Your browser doesn't support javascript.
loading
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Moretto, Roberto; Elliott, Andrew; Rossini, Daniele; Intini, Rossana; Conca, Veronica; Pietrantonio, Filippo; Sartore-Bianchi, Andrea; Antoniotti, Carlotta; Rasola, Cosimo; Scartozzi, Mario; Salati, Massimiliano; Pella, Nicoletta; Calegari, Maria Alessandra; Carullo, Martina; Corti, Francesca; Mauri, Gianluca; Fassan, Matteo; Masi, Gianluca; Brodskiy, Pavel; Lenz, Heinz-Josef; Shields, Anthony; Lonardi, Sara; Korn, Michael; Cremolini, Chiara.
Afiliação
  • Moretto R; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Elliott A; Clinical & Translational Research, Medical Affairs, Caris Life Sciences, Phoenix, AZ, USA.
  • Rossini D; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Intini R; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Conca V; Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.
  • Pietrantonio F; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Sartore-Bianchi A; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Antoniotti C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Rasola C; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Scartozzi M; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Salati M; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Pella N; Oncology Unit 1, Veneto Institute of Oncology-IRCCS, Padua, Italy.
  • Calegari MA; Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
  • Carullo M; Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
  • Corti F; Division of Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  • Mauri G; PhD Program Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
  • Fassan M; Department of Oncology, ASUFC University Hospital of Udine, Udine, Italy.
  • Masi G; Comprensive Cancer Center, UOC di Oncologia Medica, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
  • Brodskiy P; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Lenz HJ; Department of Translational Research and New Technology in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Shields A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Lonardi S; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Korn M; Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Padua, Italy.
  • Cremolini C; Veneto Institute of Oncology-IRCCS, Padua, Italy.
Br J Cancer ; 127(5): 957-967, 2022 09.
Article em En | MEDLINE | ID: mdl-35665778
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália